Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 494 entries
View as:

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PF-04958242 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01238679 Org: User:
Start: 11/24/10 End: 05/03/11 Due: 05/03/12

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Phase: N/A Priority: Normal
NCT ID: NCT01568112 Org: User:
Start: 04/30/12 End: 10/31/12 Due: 10/31/13

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03352557 Org: User:
Start: 05/03/18 End: 08/30/21 Due: 08/30/22

An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT01838668 Org: User:
Start: 03/28/13 End: 09/04/18 Due: 09/04/19

Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00292422 Org: User:
Start: 11/30/05 End: 05/31/07 Due: 05/31/08

Observational Study to Assess the Correlation of EDSS With Quality of Life in MS Participants Treated With Natalizumab

Phase: N/A Priority: Normal
NCT ID: NCT02386566 Org: User:
Start: 03/20/15 End: 01/28/18 Due: 01/28/19

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (LTE AMETHYST)

Phase: N/A Priority: Normal
NCT ID: NCT06044337 Org: User:
Start: 10/03/23 End: 12/11/29 Due: 12/11/30

Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

Phase: N/A Priority: Normal
NCT ID: NCT03068130 Org: User:
Start: 04/18/17 End: 09/30/20 Due: 09/30/21

A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINAL

Phase: N/A Priority: Normal
NCT ID: NCT03019185 Org: User:
Start: 03/02/17 End: 10/30/20 Due: 10/30/21

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT00363636 Org: User:
Start: 09/30/06 End: 04/30/10 Due: 04/30/11

Biogen Multiple Sclerosis Pregnancy Exposure Registry

Phase: N/A Priority: Normal
NCT ID: NCT01911767 Org: User:
Start: 10/30/13 End: 02/10/22 Due: 02/10/23

Study to Investigate the Effect of GSK1014802 on Ambulatory Blood Pressure

Phase: N/A Priority: Normal
NCT ID: NCT00955396 Org: User:
Start: 07/31/09 End: 12/31/09 Due: 12/31/10

Quantitative Magnetic Resonance Imaging (MRI) Sub-Study of MS PATHS

Phase: N/A Priority: Normal
NCT ID: NCT04145284 Org: User:
Start: 04/30/19 End: 04/30/20 Due: 04/30/21

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00298272 Org: User:
Start: 05/31/06 End: 07/31/11 Due: 07/31/12

A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous (SC) Natalizumab in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

Phase: N/A Priority: Normal
NCT ID: NCT05532163 Org: User:
Start: 01/23/23 End: 10/09/23 Due: 10/09/24

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00451451 Org: User:
Start: 06/30/07 End: 08/31/11 Due: 08/31/12

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Phase: N/A Priority: Normal
NCT ID: NCT01930890 Org: User:
Start: 11/30/13 End: 01/31/16 Due: 01/31/17

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00280956 Org: User:
Start: 07/31/02 End: 09/30/04 Due: 09/30/05

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Phase: N/A Priority: Normal
NCT ID: NCT03177083 Org: User:
Start: 01/30/17 End: 10/26/20 Due: 10/26/21

A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT04895241 Org: User:
Start: 05/25/21 End: 03/16/27 Due: 03/16/28

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Phase: N/A Priority: Normal
NCT ID: NCT00384150 Org: User:
Start: 11/30/07 End: 01/31/10 Due: 01/31/11

Multiple Dose Study of Aducanumab (BIIB037) (Recombinant, Fully Human Anti-Aβ IgG1 mAb) in Participants With Prodromal or Mild Alzheimer's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01677572 Org: User:
Start: 10/05/12 End: 07/31/19 Due: 07/31/20

RTA 408 Capsules in Patients With Friedreich's Ataxia - MOXIe

Phase: N/A Priority: Normal
NCT ID: NCT02255435 Org: User:
Start: 01/31/15 End: 06/27/25 Due: 06/27/26

A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03000530 Org: User:
Start: 12/07/16 End: 11/08/17 Due: 11/08/18

Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012

Phase: N/A Priority: Normal
NCT ID: NCT02579681 Org: User:
Start: 04/30/14 End: 12/21/16 Due: 12/21/17